Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease

Movement Disorders

Volumn 30, Issue 9, 2015, Pages 1222-1228

  Verhagen Metman, Leo ^a   Stover, Natividad ^b   Chen, Cuiping ^c   Cowles, Verne E ^c   Sweeney, Michael ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Depomed Inc   (United States)

Author keywords

carbidopa levodopa; efficacy; gastroretention; Parkinson's disease; pharmacokinetics

Indexed keywords

ANTIPARKINSON AGENT; CARBIDOPA; CARBIDOPA, LEVODOPA DRUG COMBINATION; DRUG COMBINATION; LEVODOPA;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; FOLLOW UP; GASTROINTESTINAL TRACT; HUMAN; MALE; MIDDLE AGED; PARKINSON DISEASE; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CARBIDOPA; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 85027921476     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26219     Document Type: Article

References (13)

1. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: A clinical and pharmacokinetic study. Arch Neurol 2005;62:9051910.
2. Verhagen Metman L, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what. Mov Disord 2000;15:3-8.
3. Hardie RJ, Malcome SL, Lees AJ, Stern GM, Allen JG. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol 1986;22:429-436.
4. Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol 2004;27:245-256.
5. Hou SY, Cowles VE, Berner B. Gastric retentive dosage forms: A review. Crit Rev Ther Drug Carrier Syst 2003;20:459-497.
6. Wade DN, Mearrick PT, Morris JL. Active transport of L-dopa in the intestine. Nature 1973;242:463-465.
7. Chen C, Cowles VE, Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food. J Clin Pharmacol 2011;51:346-358.
8. Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. Clin Neuropharmacol 2012;35:67-72.
9. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord 2004;19:1409-1413.
10. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan; 1987:153-163.
11. Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM. A 12-week, placebo-controlled study of istradefylline in Parkinson's disease. Neurology 2008;70:2233-2240.
12. LeWitt PA. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. Mov Disord 2015;30:64-72.
13. Chan PLS, Nutt JG, Holford NHG. Pharmacokinetic and pharmacodynamic changes during the first four years of Levodopa treatment in Parkinson's diease. J Pharmacokinet Pharmacodyn 2005;32:459-484.